Today's Post-Market Laggard: Cubist Pharmaceuticals (CBST)
- CBST has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $75.1 million.
- CBST is down 4.8% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CBST with the Ticky from Trade-Ideas. See the FREE profile for CBST NOW at Trade-Ideas More details on CBST: Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States. CBST has a PE ratio of 46.6. Currently there are 8 analysts that rate Cubist Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold. The average volume for Cubist Pharmaceuticals has been 952,000 shares per day over the past 30 days. Cubist has a market cap of $4.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.81 and a short float of 11.8% with 4.83 days to cover. Shares are up 53% year to date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Cubist Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Highlights from the ratings report include:
- CBST's revenue growth has slightly outpaced the industry average of 8.7%. Since the same quarter one year prior, revenues rose by 12.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The current debt-to-equity ratio, 0.35, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 4.19, which clearly demonstrates the ability to cover short-term cash needs.
- The gross profit margin for CUBIST PHARMACEUTICALS INC is currently very high, coming in at 79.41%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, CBST's net profit margin of 5.88% significantly trails the industry average.
- Compared to its closing price of one year ago, CBST's share price has jumped by 40.22%, exceeding the performance of the broader market during that same time frame. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
- You can view the full Cubist Pharmaceuticals Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV